Results 51 to 60 of about 58,205 (308)

Novel IDH1-Targeted Glioma Therapies

CNS Drugs, 2019
Mutations in the isocitrate dehydrogenase (IDH) 1 gene are commonly found in human glioma, with the majority of low-grade gliomas harboring a recurrent point mutation (IDH1 R132H). Mutant IDH reveals an altered enzymatic activity leading to the synthesis of 2-hydroxyglutarate, which has been implicated in epigenetic mechanisms of oncogenesis ...
Georg, Karpel-Massler, Trang T T, Nguyen, Enyuan, Shang, Markus D, Siegelin   +3 more
openaire   +3 more sources

HDAC1 and HDAC6 are essential for driving growth in IDH1 mutant glioma

Scientific Reports, 2023
Low-grade and secondary high-grade gliomas frequently contain mutations in the IDH1 or IDH2 metabolic enzymes that are hypothesized to drive tumorigenesis by inhibiting many of the chromatin-regulating enzymes that regulate DNA structure.
Matthew C. Garrett, Rebecca Albano, Troy Carnwath, Lubayna Elahi, Catherine A. Behrmann, Merissa Pemberton, Daniel Woo, Eric O’Brien, Brett VanCauwenbergh, John Perentesis, Sanjit Shah, Matthew Hagan, Ady Kendler, Chuntao Zhao, Aditi Paranjpe, Krishna Roskin, Harley Kornblum, David R. Plas, Q. Richard Lu   +18 more
doaj   +1 more source

IDH1, Histone Methylation, and So Forth [PDF]

Cancer Cell, 2016
IDH mutants cause aberrant DNA and histone methylation and contribute to hematological and neuronal malignancies. In this issue of Cancer Cell, Inoue et al. describe a potential specific effect of IDH1 mutations that reduces Atm expression via inhibition of H3K9 demethylases, which may represent a first step toward cellular transformation.
Virginie, Penard-Lacronique, Olivier A, Bernard   +1 more
openaire   +4 more sources

Combination treatment of an IDH1 inhibitor with chemotherapy in IDH1 mutant acute myeloid leukemia [PDF]

Annals of Hematology, 2020
Patients with newly diagnosed chronic phase chronic myeloid leukemia (CP CML) can be effectively treated with tyrosine kinase inhibitors (TKIs) and achieve a lifespan similar to the general population. The success of TKIs, however, requires long-term and sometimes lifelong treatment; thus, patient-assessed health-related quality of life (HRQoL) has ...
Gupta, Charu, Kaulfuss, Stefan, Görlich, Kerstin, Othman, Basem, Chaturvedi, Anuhar, Heuser, Michael   +5 more
openaire   +3 more sources

Nicotinamide N‐methyltransferase promotes drug resistance in lung cancer, as revealed by nascent proteomic profiling

Molecular Oncology, EarlyView.
AZD9291 has shown promise in targeted cancer therapy but is limited by resistance. In this study, we employed metabolic labeling and LC–MS/MS to profile time‐resolved nascent protein perturbations, allowing dynamic tracking of drug‐responsive proteins. We demonstrated that increased NNMT expression is associated with drug resistance, highlighting NNMT ...
Zhanwu Hou, Zhen Wang, Fei Yang, Xiao Han, Lei Li, Huadong Liu   +5 more
wiley   +1 more source

Correlation of IDH1 mutation with clinicopathologic factors and prognosis in primary glioblastoma: a report of 118 patients from China. [PDF]

PLoS ONE, 2012
It has been reported that IDH1 (IDH1R132) mutation was a frequent genomic alteration in grade II and grade III glial tumors but rare in primary glioblastoma (pGBM).
Wei Yan, Wei Zhang, Gan You, Zhaoshi Bao, Yongzhi Wang, Yanwei Liu, Chunsheng Kang, Yongping You, Lei Wang, Tao Jiang   +9 more
doaj   +1 more source

Potential therapeutic targeting of BKCa channels in glioblastoma treatment

Molecular Oncology, EarlyView.
This review summarizes current insights into the role of BKCa and mitoBKCa channels in glioblastoma biology, their potential classification as oncochannels, and the emerging pharmacological strategies targeting these channels, emphasizing the translational challenges in developing BKCa‐directed therapies for glioblastoma treatment.
Kamila Maliszewska‐Olejniczak, Karolina Pytlak, Sandra Jaworowska, Bogusz Kulawiak, Piotr Bednarczyk   +4 more
wiley   +1 more source

Association of TP53 Alteration with Tissue Specificity and Patient Outcome of IDH1-Mutant Glioma

Cells, 2021
Since the initial discovery of recurrent isocitrate dehydrogenase 1 (IDH1) mutations at Arg132 in glioma, IDH1 hotspot mutations have been identified in cholangiocarcinoma, chondrosarcoma, leukemia, and various other types of cancer of sporadic incidence.
Balazs Murnyak, L. Eric Huang
doaj   +1 more source

Oncogenic R132 IDH1 Mutations Limit NADPH for De Novo Lipogenesis through (D)2-Hydroxyglutarate Production in Fibrosarcoma Sells. [PDF]

, 2018
Neomorphic mutations in NADP-dependent isocitrate dehydrogenases (IDH1 and IDH2) contribute to tumorigenesis in several cancers. Although significant research has focused on the hypermethylation phenotypes associated with (D)2-hydroxyglutarate (D2HG ...
Badur, Mehmet G, Cordes, Thekla, Guan, Kun-Liang, Ma, Shenghong, Magana, Jose H, McBrayer, Samuel K, Metallo, Christian M, Muthusamy, Thangaselvam, Parker, Seth J   +8 more
core  

The role of EGFR double minutes in modulating the response of malignant gliomas to radiotherapy. [PDF]

, 2017
EGFR amplification in cells having double minute chromosomes (DM) is commonly found in glioblastoma multiforme (GBM); however, how much it contributes to the current failure to treat GBM successfully is unknown.
Atkin, Naomi, Chen, Yumay, Gau, Alex, Giedzinski, Erich, Hu, Yuanjie, Lee, Nathan, Limoli, Charles, Linskey, Mark E, Ly, Khang Chi, Pan, Francine, Qiao, Jiao, Ru, Ning, Siegel, Eric R, Tran, Katherine, Wang, Ping, Yu, Liping, Zhou, Yi-Hong   +16 more
core   +1 more source